Error loading player: No playable sources found

89828

Parallel Session 3 - Viral Vector-based Gene Therapy Products

Date
June 11, 2024
This product is not available for individual purchase, but it is available as part of the following products:

The field of Cell and Gene Therapy has witnessed expanding numbers of regulatory approvals in recent years. Of the approved products, a significant number are viral vector-based, either employing the viral vector for the delivery of a therapeutic transgene to cells ex vivo during the manufacturing process (e.g., LVV for modified cells), or via direct administration to the patient (e.g., AAV-based gene therapy product) to achieve a therapeutic effect. Given the rate of recent approvals, coupled with technological advances in molecular sciences, and partly driven by evolving regulatory expectations around controls, there is an evolution of product understanding, particularly in the application of analytical methods used to support process development and characterize or monitor product attributes. The aim of this session is to examine these changes in greater detail, including analytical method choices for optimal assessment of product characteristics, attribute criticality and monitoring. This may also include innovative approaches to determination of potency, including the use of surrogate metrics in the context of a potency assay matrix. A greater scientific understanding of viral vector-based Gene Therapy product attributes will improve the overall quality of these important therapeutic products. 


Session Speakers:


LYFGENIA's Journey: Lessons Learned in the Development of LVV-based Cell & Gene Therapy Products

Marc d'Anjoubluebird bio, Inc. 


Potency Method Development, Bridging and Control Strategies for AAV Gene Therapy

Ping Carlson, Passage Bio


Gene Therapy Product Analytics: Potency Method Validation and Optimization

Wandong Zhang, BioMarin Pharamceutical Inc.



Additional Panelist:


Jessica CheryCBER, FDA


Related Products

Thumbnail for Parallel Session 2 - How to Control Off Target Genotoxicity for Genome and Epigenome Editing Medicines
Parallel Session 2 - How to Control Off Target Genotoxicity for Genome and Epigenome Editing Medicines
Genome editing is a tool that enables a new generation of medicines by directly targeting with high precision the genetic cause of a disease. It also allows for immune evasion and prevents microenvironment responses: concepts vital to more potent, off the shelf, cell, and gene therapies…
Thumbnail for Hot Topic Session - ICH Cell & Gene Therapy Discussion Group Updates
Hot Topic Session - ICH Cell & Gene Therapy Discussion Group Updates
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together regulatory authorities and representatives from the pharmaceutical industry from across the globe to discuss a range of technical and scientific considerations for medicinal…
Thumbnail for Plenary Session 6 - Fireside Chat: Evolution of Cell and Gene Therapy
Plenary Session 6 - Fireside Chat: Evolution of Cell and Gene Therapy
Join us for an engaging fireside chat delving into the revolutionary landscape of cell and gene therapy…